PBAC's latest decision on Budesonide / glycopyrronium / formoterol: Recommended with restriction (2021). Considered for Maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate to very severe COPD who require treatment with a combination of an ICS, a LABA, and a LAMA.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2021
Submissions
1
2021 → 2021
Eligible population
Adults with moderate to very severe COPD who have experienced at least one severe exacerbation requiring hospitalisation, or two or more moderate exacerbations in the previous 12 months, despite regular bronchodilator therapy, or who have been stabilised on a combination of LAMA, LABA and ICS.